FindTrial
Sign In

Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508233-14-00
Acronym
U31402-0002-CESR-MA
Enrollment
16
Registered
2024-07-15
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR mutation positive advanced stage NSCLC

Brief summary

The optimal imaging dose patritumab deruxtecan to co-inject with 89Zr-Patritumab deruxtecan (HER3-DXd), defined by adequate visualisation of the circulation five days after tracer injection.

Detailed description

SUV of tumor lesions.

Interventions

DRUGPatritumab Deruxtecan
DRUGZIRCONIUM (89Zr) Patritumab Deruxtecan

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The optimal imaging dose patritumab deruxtecan to co-inject with 89Zr-Patritumab deruxtecan (HER3-DXd), defined by adequate visualisation of the circulation five days after tracer injection.—

Secondary

MeasureTime frame
SUV of tumor lesions.—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026